Nektar Therapeutics Ownership | Who Owns Nektar Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Nektar Therapeutics Ownership Summary


Nektar Therapeutics is owned by 146.02% institutional investors, 0.45% insiders. Fmr is the largest institutional shareholder, holding 20.49% of NKTR shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 6.86% of its assets in Nektar Therapeutics shares.

NKTR Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockNektar Therapeutics146.02%0.45%-46.46%
SectorHealthcare Stocks 244.59%12.11%-156.70%
IndustryBiotech Stocks 379.61%11.70%-291.31%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr5.07M20.49%$353.79M
Two seas capital lp3.09M12.50%$215.87M
Blackrock funding, inc. /de2.94M11.89%$205.37M
Bvf inc/il2.39M9.67%$166.92M
Blackrock15.16M7.78%$18.79M
Vanguard group1.03M7.29%$43.43M
Vanguard capital management1.50M6.05%$104.50M
Two sigma investments, lp1.20M4.86%$83.91M
Vestal point capital, lp1.00M4.04%$69.81M
Morgan stanley936.56K3.79%$65.38M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
22nw, lp281.12K18.75%$19.62M
Prosight management, lp810.00K9.74%$56.55M
Apeiron capital106.43K4.77%$7.43M
Two seas capital lp3.09M4.28%$215.87M
Bvf inc/il2.39M4.27%$166.92M
Dafna capital management318.38K4.24%$22.23M
Act capital management89.30K4.07%$6.23M
Stonepine capital management120.65K3.94%$8.42M
Superstring capital management lp51.27K2.87%$2.92M
Birchview capital, lp81.00K2.64%$5.65M

Top Buyers

HolderShares% AssetsChange
Blackrock15.16M0.00%9.28M
Altium capital management lp3.00M0.79%2.99M
Blackrock funding, inc. /de2.94M0.00%2.25M
Two seas capital lp3.09M4.28%1.13M
Fmr5.07M0.02%764.73K

Top Sellers

HolderShares% AssetsChange
Samlyn capital---9.67M
Eventide asset management---6.65M
Almitas capital---4.61M
Lynx1 capital management lp---2.07M
Assenagon asset management---1.69M

New Positions

HolderShares% AssetsChangeValue
Deep track capital, lp300.00K0.30%300.00K$20.94M
Sixth street partners management company284.97K0.00%284.97K$19.89M
Norges bank215.30K0.00%215.30K$15.03M
Two sigma advisers, lp178.91K0.02%178.91K$10.18M
Soleus capital management128.36K0.31%128.36K$8.96M

Sold Out

HolderChange
Salomon & ludwin-3.00
Mai capital management-4.00
Clearstead advisors-5.00
Cornerstone planning group-5.00
Arlington trust-6.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202625716.82%36,119,00535.28%1460.84%17721.23%44-2.22%
Mar 31, 202621415.05%26,436,04552.71%1300.86%14127.03%44-
Dec 31, 202568-57.23%5,169,695-64.12%360.35%44-59.26%14-48.15%
Sep 30, 202537-66.36%1,954,060-74.48%130.47%24-17.24%6-91.67%
Jun 30, 202537-77.30%2,048,084-98.35%140.42%10-86.49%27-44.90%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl S2.32M6.86%-
Fidelity Growth Company Fund1.83M5.42%-2.26K
Eventide Healthcare & Life Sciences I6.65M3.57%-
Vanguard Total Stock Mkt Idx Inv1.08M3.18%47.84K
Vanguard Morn Total Stk Mkt Idx Investor1.08M3.18%47.84K
Vanguard MStar Total Stk Mkt Idx Invest1.08M3.16%3.91K
Vanguard US Total Market Shares ETF5.72M3.08%-
iShares Russell 2000 ETF876.68K2.59%-15.55K
Fidelity Growth Company K6495.04K1.47%2.26K
Fidelity Series Growth Company419.82K1.24%-

Recent Insider Transactions


DateNameRoleActivityValue
Aug 18, 2026Zalevsky Jonathan Chief R&D OfficerSell$13.39K
Aug 18, 2026ROBIN HOWARD W President & CEOSell$30.09K
Jun 30, 2026Zalevsky Jonathan Chief R&D OfficerSell$397.67K
Jun 16, 2026ROBIN HOWARD W President & CEOSell$285.15K
Jun 17, 2026ROBIN HOWARD W President & CEOSell$334.45K

Insider Transactions Trends


DateBuySell
2026 Q3-2
2026 Q2-8
2026 Q1-3
2025 Q4-3
2025 Q3-20

NKTR Ownership FAQ


Who Owns Nektar Therapeutics?

Nektar Therapeutics shareholders are primarily institutional investors at 146.02%, followed by 0.45% insiders and -46.47% retail investors. The average institutional ownership in Nektar Therapeutics's industry, Biotech Stocks , is 379.61%, which Nektar Therapeutics falls below.

Who owns the most shares of Nektar Therapeutics?

Nektar Therapeutics’s largest shareholders are Fmr (5.07M shares, 20.49%), Two seas capital lp (3.09M shares, 12.50%), and Blackrock funding, inc. /de (2.94M shares, 11.89%). Together, they hold 44.88% of Nektar Therapeutics’s total shares outstanding.

Does Blackrock own Nektar Therapeutics?

Yes, BlackRock owns 7.78% of Nektar Therapeutics, totaling 15.16M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 18.79M$. In the last quarter, BlackRock increased its holdings by 9.28M shares, a 157.82% change.

Who is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested?

22nw, lp is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested, with 18.75% of its assets in 281.12K Nektar Therapeutics shares, valued at 19.62M$.

Who is the top mutual fund holder of Nektar Therapeutics shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Nektar Therapeutics shares, with 6.86% of its total shares outstanding invested in 2.32M Nektar Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools